Aurora Investment Managers LLC. Takes $200,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Aurora Investment Managers LLC. acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,707 shares of the medical research company’s stock, valued at approximately $200,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Harbor Investment Advisory LLC raised its position in shares of Edwards Lifesciences by 8.8% in the fourth quarter. Harbor Investment Advisory LLC now owns 17,825 shares of the medical research company’s stock valued at $1,320,000 after buying an additional 1,442 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Edwards Lifesciences by 1.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 21,076 shares of the medical research company’s stock worth $1,560,000 after acquiring an additional 256 shares during the period. Purus Wealth Management LLC raised its holdings in Edwards Lifesciences by 10.9% in the 4th quarter. Purus Wealth Management LLC now owns 3,589 shares of the medical research company’s stock valued at $266,000 after acquiring an additional 354 shares during the last quarter. Seilern Investment Management Ltd acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $109,490,000. Finally, Diversify Wealth Management LLC grew its position in shares of Edwards Lifesciences by 99.9% in the fourth quarter. Diversify Wealth Management LLC now owns 37,441 shares of the medical research company’s stock valued at $2,749,000 after purchasing an additional 18,715 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.1 %

Shares of Edwards Lifesciences stock opened at $69.77 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50-day moving average of $72.06 and a 200-day moving average of $71.18. The company has a market capitalization of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 over the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a research report on Thursday, January 16th. Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.